Advances in the treatment of KPC-producing Klebsiella pneumoniae infec-tion
10.12138/j.issn.1671-9638.20243595
- VernacularTitle:产KPC肺炎克雷伯菌感染治疗的研究进展
- Author:
Yan-Qiu MA
1
;
Zhen-Chao WU
;
Yi-Peng DU
;
Ning SHEN
Author Information
1. 北京大学第三医院呼吸与危重症医学科,北京 100191
- Keywords:
Klebsiella pneumoniae;
carbapenemase;
treatment;
meropenem/vaborbactam;
ceftazidime/avibactam
- From:
Chinese Journal of Infection Control
2024;23(2):250-256
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,the isolation rate of carbapenem-resistant Klebsiella pneunoniae(CRKP)in China has increased year by year.Due to its multidrug resistance and high mortality in patients,CRKP brings severe challen-ges to the clinical treatment.The major mechanism of drug resistance in CRKP is the production of carbapenemases,with Ambler A,B,and D being the common types while Ambler type C comparativly rare.Klebsiella pneumoniae carbapenemase(KPC)is the most common carbapenemase,which belongs to type A.KPC-producing Klebsiella pneumoniae(KPC-KP)widely spreads in the world,with very limited number of effective clinical drugs.In this re-view,advances in the treatment KPC-KP were summarized to provide reference for clinical treatment.
